The rabbit skin irritation test is a well-established in vivo biocompatibility assay used to evaluate whether medical devices, materials, chemicals, or cosmetic formulations can cause reversible inflammatory damage to the skin. Performed in accordance with recognized standards such as ISO 10993-23, OECD Test Guideline 404, and GB/T 16886.23, this test plays a critical role in regulatory submissions for the medical device, cosmetic, and chemical industries. This article provides a comprehensive technical overview of the test principle, sample preparation, experimental procedure, scoring criteria, and practical applications.
Technical Overview
The rabbit skin irritation test, also known historically as the Draize primary skin irritation test or acute dermal irritation test, is an in vivo toxicology assay designed to assess the potential of a test material, or an extract prepared from it, to produce a localized, reversible inflammatory response following topical contact with intact mammalian skin. The characteristic endpoints of irritation are erythema (redness caused by vascular congestion) and edema (swelling caused by fluid accumulation in tissue).
New Zealand White rabbits are the preferred animal model because their skin is relatively thin and permeable, and historical validation data indicate that rabbit skin tends to be more sensitive than human skin. This provides a conservative safety margin when predicting human dermal responses. Healthy adult animals with intact, unbroken skin are selected, and modern protocols typically require the minimum number of animals necessary to obtain scientifically valid results, in line with the 3Rs principles (Replacement, Reduction, and Refinement).
Governing Standards
- ISO 10993-23 — Biological evaluation of medical devices, Part 23: Tests for irritation (this part superseded the irritation content formerly located in ISO 10993-10)
- GB/T 16886.23 — The Chinese national adoption of ISO 10993-23 for medical device irritation testing
- OECD Test Guideline 404 — Acute Dermal Irritation/Corrosion for industrial chemicals and pesticide registration
- ISO 10993-12 — Sample preparation and reference materials, which governs extraction conditions for medical device testing
- ISO 10993-10 — Tests for skin sensitization, which addresses the immunologically mediated response often evaluated alongside irritation
It is important to distinguish skin irritation from two related but distinct hazard categories. Skin corrosion refers to the production of irreversible tissue damage, such as necrosis extending through the epidermis into the dermis, whereas irritation is by definition reversible. Skin sensitization is a delayed Type IV hypersensitivity reaction involving the immune system, which is assessed under a separate testing strategy. The rabbit skin irritation test addresses only the local, non-immunological inflammatory endpoint.
Accredited third-party laboratories operating under Good Laboratory Practice (GLP) principles routinely conduct this test to support regulatory submissions in major markets, including China, the United States, the European Union, and Japan.
Testing Samples
Medical Devices and Biomaterials
For medical devices that contact intact or breached skin, or whose extracts may reach skin tissue, the test is generally performed on solvent extracts rather than on the device directly. Typical product categories include wound dressings, adhesive bandages and tapes, medical electrodes, examination and surgical gloves, syringes and infusion sets, catheter components, face masks, tubing sets, orthopedic implant materials, and device packaging systems that contact the product.
Cosmetics and Personal Care Products
Finished formulations such as creams, lotions, sunscreens, cleansing products, and hair care preparations may be evaluated using this method in jurisdictions where in vivo safety data remains acceptable for regulatory purposes. In regions such as the European Union, where animal testing for cosmetics is prohibited, validated in vitro alternatives must be used instead.
Chemicals and Industrial Products
Industrial chemicals, agrochemicals, disinfectants, household cleaning products, detergents, and other substances subject to hazard classification under the Globally Harmonized System (GHS) or chemical registration programs such as REACH can be tested as neat substances or at appropriate dilutions.
Sample Preparation and Extraction
For medical device testing, extracts are prepared in accordance with ISO 10993-12 using both a polar and a non-polar vehicle to maximize the extraction of potentially irritant leachables:
- Polar vehicle — physiological saline (0.9% sodium chloride injection)
- Non-polar vehicle — freshly refined vegetable oil, such as sesame seed oil or cottonseed oil of pharmacopeial grade
- Justified alternative vehicles — such as ethanol/water mixtures, polyethylene glycol 400, or dimethyl sulfoxide, when scientifically warranted
Standard extraction ratios are approximately 3 cm² of material surface area per milliliter of vehicle (or 6 cm²/mL for materials with a thickness of 0.5 mm or less), and approximately 0.2 g of material per milliliter for irregularly shaped solids. Common extraction conditions include (37 ± 1) °C for (72 ± 2) hours, (50 ± 2) °C for (72 ± 2) hours, (70 ± 2) °C for (24 ± 2) hours, or (121 ± 2) °C for (1 ± 0.1) hours, with the condition selected to be clinically representative yet not thermally degrading to the material.
Testing Items
The core deliverables of the rabbit skin irritation test include the following:
- Acute primary skin irritation assessment following a single, time-limited (typically four-hour) semi-occlusive or occlusive exposure
- Dermal observation for erythema and eschar formation at defined time points
- Dermal observation for edema at defined time points
- Calculation of the Primary Irritation Index (PII) and assignment of an irritation classification category
- Documentation of any additional local observations, such as desquamation, fissuring, or desiccation
- Monitoring of animals for general health, clinical abnormalities, and body weight changes throughout the observation period
- Comparison of test-site responses against paired vehicle control sites to isolate the irritant contribution of the test material
For certain product categories, such as materials intended for prolonged cumulative skin contact, a repeated-exposure (cumulative) irritation study design may be justified as an extension of the single-exposure protocol.
Testing Methods
Animal Selection and Preparation
Healthy adult New Zealand White rabbits, typically weighing 2 kg or more, are acclimated to laboratory housing for at least five days before the study begins. Animals are housed individually under controlled environmental conditions with ad libitum access to food and water. Approximately 24 hours before dosing, the fur on the dorsal area and flanks is closely clipped, taking care to avoid abrading the skin. Only animals with intact, unbroken skin are used. Modern ISO 10993-23 protocols require application to intact skin only; the use of abraded skin sites from historical Draize protocols has been discontinued.
Test Procedure
The general experimental sequence is as follows:
- A measured dose of the test substance (commonly 0.5 mL of liquid or 0.5 g of solid or extract-moistened gauze) is applied to an absorbent patch of approximately 2.5 cm × 2.5 cm
- The patch is placed on the clipped dorsal skin of the test site, and the corresponding vehicle control is applied to a contralateral control site
- The application is covered with an occlusive or semi-occlusive dressing to maintain contact and prevent cross-contamination between sites
- The exposure period is maintained for approximately four hours, after which the dressing and patch are removed and the skin is gently cleaned with warm water or saline to remove residual material
- Skin reactions are evaluated at 1 hour (approximately 60 minutes) after patch removal, and again at 24, 48, and 72 hours
- Observation is extended, up to 14 days if necessary, when persistent reactions are observed
- Humane endpoints are predefined, and animals showing severe distress or corrosive injury are withdrawn from the study and humanely managed
Scoring Criteria
Skin reactions are graded using the standardized Draize scoring scale. Each observation yields a total of up to 8 points per site (4 for erythema plus 4 for edema).
Erythema and eschar formation:
- 0 — No erythema
- 1 — Very slight erythema, barely perceptible
- 2 — Well-defined erythema
- 3 — Moderate to severe erythema
- 4 — Severe erythema (beet redness) to slight eschar formation preventing reading of erythema
Edema formation:
- 0 — No edema
- 1 — Very slight edema, barely perceptible
- 2 — Slight edema, with edges of the swelling well defined by definite raising
- 3 — Moderate edema, raised approximately 1 mm
- 4 — Severe edema, raised more than 1 mm and extending beyond the area of exposure
Calculation of the Primary Irritation Index
The Primary Irritation Index (PII) is calculated by summing all erythema and edema scores recorded for the test sites across all animals and all observation time points, and dividing this total by the number of individual readings taken. Where vehicle-related responses occur, control-site scores are subtracted from corresponding test-site scores so that the final index reflects the irritant potential attributable to the test material itself.
Result Interpretation
The calculated PII is mapped to a standard classification scheme:
- 0.0 to 0.4 — Negligible irritation
- 0.5 to 1.9 — Slight irritation
- 2.0 to 4.9 — Moderate irritation
- 5.0 to 8.0 — Severe irritation
A study is considered valid when the vehicle control sites exhibit no significant irritant response, confirming that any reaction observed at the test sites is attributable to the test material. A result in the negligible range generally supports a claim that the material is non-irritant to skin for regulatory purposes, whereas moderate or severe findings typically trigger risk mitigation measures, revised labeling, material reformulation, or additional biological evaluation.
Applications
The rabbit skin irritation test supports a wide range of regulatory, quality, and research objectives:
- Medical device biocompatibility evaluation — forming part of the biological evaluation plan required for market authorization under frameworks such as EU MDR, US FDA submissions, Japan's pharmaceutical and medical device regulations, and China's NMPA registration process
- Chemical hazard classification and labeling — supporting GHS/CLP categorization for skin irritancy, REACH registration dossiers, and the transport of dangerous goods
- Cosmetic and personal care safety assessment — providing dermal tolerance data in jurisdictions where in vivo testing remains acceptable
- Disinfectant and pesticide registration — demonstrating dermal safety for products intended for institutional, agricultural, or household use
- Research and development — screening candidate materials, formulations, and surface treatments early in the design cycle to eliminate irritant liabilities
- Quality control and change control — verifying that modifications to materials, suppliers, sterilization methods, or manufacturing processes do not alter the dermal irritation profile of a marketed product
For medical devices, the test is prioritized for categories with skin-contacting or skin-breach clinical use, and the overall biological evaluation is typically structured according to the ISO 10993-1 risk management framework, with irritation testing performed alongside cytotoxicity and sensitization assessments as the core screening triad.
FAQ
Why are rabbits used rather than other animal species?
Rabbits offer a combination of large, accessible dorsal test sites, thin and sensitive skin, extensive historical databases, and an established correlation with human outcomes. Their tendency to respond somewhat more sensitively than humans provides a conservative margin of safety, which is valued in regulatory toxicology.
How is skin irritation different from skin sensitization and corrosion?
Irritation is a localized, reversible inflammatory reaction that appears shortly after exposure and resolves after exposure ceases. Corrosion involves irreversible tissue destruction and necrosis. Sensitization is an immune-mediated delayed hypersensitivity that requires prior induction and escalates upon re-exposure; it is assessed under separate standards such as ISO 10993-10.
Can the rabbit skin irritation test be replaced by in vitro methods?
Validated in vitro alternatives based on reconstructed human epidermis (RhE) models are accepted for many regulatory applications under OECD Test Guideline 439, particularly for chemicals and cosmetics. However, in vivo testing remains necessary or preferred in certain situations, such as complex medical device extracts, poorly defined multi-component materials, or cases where in vitro results are inconclusive. A testing strategy based on a weight-of-evidence approach is generally recommended.
How many animals are required and how long does the study take?
A standard acute study typically uses three rabbits in accordance with ISO 10993-23. Including acclimation, application, observation, and reporting, the in-life and reporting phase is generally completed within two to four weeks. Extraction of medical device samples may add additional time depending on the extraction condition selected.
How much sample is needed for testing?
For medical device extracts, the required quantity depends on the surface area or mass of the device, calculated to satisfy the extraction ratios defined in ISO 10993-12 for both polar and non-polar vehicles. As a practical guideline, laboratories commonly request several grams of material or a representative number of finished devices to ensure sufficient extract volume for treatment and control replicates.
What result is considered acceptable for regulatory submission?
A Primary Irritation Index in the negligible range (0.0 to 0.4), with valid vehicle controls and no abnormal systemic findings, is generally accepted as evidence that the test material does not present a dermal irritation hazard. Acceptance ultimately depends on the applicable regulatory framework and the intended duration and nature of clinical skin contact.
Is this test accepted for cosmetics in all markets?
No. The European Union and several other jurisdictions prohibit animal testing for cosmetic products and ingredients. In these markets, dermal tolerance must be demonstrated using validated in vitro methods and existing safety data. Manufacturers should confirm the specific requirements of each target market before commissioning testing through an accredited third-party laboratory.